SH3TC2 and demyelinating polyneuropathy: Establishing the expression pattern of the endogenous protein is therefore vital both to understand why mutations in SH3TC2 lead specifically to a demyelinating peripheral neuropathy and also to devise potential therapeutic strategies for this and other subtypes of CMT.